Your prediction
Takeda Pharmaceutical Co Ltd Stock
With only a change of €0.020 (0.070%) the Takeda Pharmaceutical Co Ltd price is nearly unchanged from yesterday.
Our community identified positive and negative aspects for Takeda Pharmaceutical Co Ltd stock for the coming years. 1 users see the criterium "Business model" as a plus for the Takeda Pharmaceutical Co Ltd stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Takeda Pharmaceutical Co Ltd in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Takeda Pharmaceutical Co Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 0.070% | -1.785% | 6.794% | 22.667% | 13.657% | 7.645% | 6.031% |
| Santen Pharmaceutical Corp Ltd. | 0.990% | -2.885% | -10.619% | 5.759% | 16.092% | 29.487% | -9.821% |
| Chugai Pharmaceutical Co Ltd | 0.050% | -6.011% | -4.657% | -12.779% | -17.663% | 33.309% | 15.524% |
| Eisai Co Ltd | 0.550% | 3.820% | 16.507% | 4.885% | 0.196% | -56.100% | -63.237% |
Comments
News
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook